Investigational Drug Information for Lestaurtinib
✉ Email this page to a colleague
What is the development status for investigational drug Lestaurtinib?
Lestaurtinib is an investigational drug.
There have been 8 clinical trials for Lestaurtinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 14th 2008.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Thrombocythemia, Essential. The leading clinical trial sponsors are National Cancer Institute (NCI), Cephalon, and Children's Oncology Group.
Summary for Lestaurtinib
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,857 |
| WIPO Patent Applications | 1,354 |
| Japanese Patent Applications | 276 |
| Clinical Trial Progress | Phase 2 (2008-01-14) |
| Vendors | 64 |
Recent Clinical Trials for Lestaurtinib
| Title | Sponsor | Phase |
|---|---|---|
| Ponatinib for FLT3-ITD Acute Myelogenous Leukemia | Versailles Hospital | Phase 1/Phase 2 |
| CEP-701 (Lestaurtinib) in Myelofibrosis | Myeloproliferative Disorders-Research Consortium | Phase 1/Phase 2 |
| CEP-701 (Lestaurtinib) in Myelofibrosis | National Cancer Institute (NCI) | Phase 1/Phase 2 |
Clinical Trial Summary for Lestaurtinib
Top disease conditions for Lestaurtinib
Top clinical trial sponsors for Lestaurtinib
US Patents for Lestaurtinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
